Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities
Anti-Smoking Legislation Vital for Nicotine Addiction to go up in Smoke, says Report
Anti-smoking legislation and structured support from healthcare providers is essential to achieve widespread smoking cessation, claims a new report by healthcare experts GBI Research.
The new report* argues that the effectiveness of current pharmaceutical treatments depends as much on enforced legislation, such as smoking bans, and support from healthcare providers as an individual's willingness to quit.
According to the World Health Organization (WHO), up to half of all 'lifelong' tobacco users will die from a tobacco-related disease, while the five million deaths that occur as a result of smoking every year outnumber the collective lives lost to HIV/AIDS, malaria and tuberculosis. Nicotine addiction therefore represents a serious public health risk and must be met with effective cessation therapies.
GBI Research claims that the prevalent population for nicotine addiction stood at 136.7 million in 2011, while the 'diagnosed' population, defined as those going to visit a physician concerning smoking cessation, was only 40 million. Furthermore, GlaxoSmithKline claims that while 70% of smokers want to quit less than 5% actually do, indicating a massive opportunity for companies willing to enter the market.
Popular Nicotine Replacement Therapies (NRTs) are conveniently available over-the-counter and account for 75% of all smoking cessation therapies sold worldwide, with patches, gum, lozenges, sprays and inhalers available to deliver doses of nicotine and reduce the effects of withdrawal.
FDA-approved prescription medications for smoking cessation include the nicotine receptor agonist Chantix (varenicline) and the antidepressant Buproprion (marketed as Zyban, Wellbutrin, Voxra, Budeprion, and Aplenzin). However, while these drugs act to alleviate nicotine withdrawal symptoms and the severity of nicotine cravings, both carry associated risks of suicidal tendencies, with Chantix having been forced to carry a 'black box' warning since 2008.
The increasing emergence of smokeless electronic 'e-cigarette' products have split opinion as effective treatments as, while e-cigarettes are often marketed as anti-smoking treatments, they are often sponsored by large tobacco companies and arguably serve to keep smokers addicted. Furthermore, the 'e-cigarette' market is currently unregulated, while low-grade nicotine is often used, which may have unpleasant and possibly dangerous side-effects.
The report states that increasing numbers of patients seeking treatment are being supported by healthcare campaigns around the world. Government efforts are evident in the UK, where the NHS Stop Smoking service enabled over half a million patients to access smoking cessation therapy during April 2011-December 2011 alone.
The report goes on to indicate that future revenues will be made from smoking cessation therapies in countries where legislation and healthcare campaigns are not yet present. South East Asia represents a huge potential market for the next 15 years, as a very high smoking prevalence rate is contrasted with the lack of an established market for NRT or anti-smoking products. GBI Research healthcare analyst, Amy Baker, said: "This market is as yet largely untapped because of cultural attitudes to smoking and a lack of public health efforts; but, should any companies in the future crack the Asian markets, it will offer a massive opportunity."
The global nicotine addiction therapeutics market was estimated at $4.5 billion in 2011, indicating a CAGR of 3.1% between 2004 and 2011. The value is expected to reach $6.2 billion in 2018, following growth at a CAGR of 4.5% between 2011 and 2018.
Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities
The report provides insights into the substance abuse therapeutics market, including market forecasts up to 2018, and an in-depth analysis of the major substance abuse indications, which include nicotine addiction, alcohol dependence and opioid and cocaine abuse. It additionally gives insights into the substance abuse therapeutics R&D pipeline, and analyzes the competitive landscape through the analysis of M&A and licensing deals.
The report is built using data and information sourced from proprietary databases, primary and secondary secondary research, and in-house analysis conducted by GBI Research's team of industry experts.
Abstract
Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities
Summary
GBI Research, leading business intelligence provider has released its latest research report, entitled "Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities". The report provides insights into the substance abuse therapeutics market including market forecasts up to 2018. It provides an in-depth analysis of the major substance abuse indications, which include nicotine addiction, alcohol dependence and opioid and cocaine abuse, as well as insights into the substance abuse therapeutics R&D pipeline. In addition, it analyzes the competitive landscape through the analysis of M&A and licensing deals.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
GBI Research finds that the substance abuse therapeutics market in the top seven markets was valued at $8.8 billion in 2011, increasing at a CAGR of 4.9% during the review period 2004-2011. The market is projected to witness moderate growth of 5.3% during the 2011-2018 forecast period to reach $12.7 billion. The moderate growth of the market can be attributed to the presence of generics in the market, low compliance with therapy due to the nature of addiction and the lack of innovative products in the pipeline. However, indications such as cocaine addiction, which currently have no approved products, are expected to see entries to the market and high-priced products such as Champix for smoking cessation will not see patent expiry in the forecast period.
Scope
Data and analysis on the substance abuse therapeutics market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
Annualized market data for the substance abuse therapeutics market from 2004-2011 with forecasts to 2018.
Market data on the therapeutic landscape, which covers nicotine addiction, alcohol dependence and opioid and cocaine abuse. This includes market size, annual cost of therapy, treatment flow algorithm.
Key drivers and restraints that have had a significant impact on the market and on each indication.
The competitive landscape of the global substance abuse therapeutics market, which includes companies such as Pfizer, GSK, Forest Laboratories, Alkermes and Reckitt Benckiser.
Key M&A activities and licensing agreements that took place from 2007 to 2011 in the global substance abuse therapeutics market.
Reasons to buy
Align your product portfolio to the markets with high growth potential.
Develop market-entry and market expansion strategies by identifying the potential region and substance abuse therapeutics market segments poised for strong growth.
Create a more tailored country strategy through the understanding of key drivers and barriers of the global substance abuse therapeutics market.
Develop key strategic initiatives by understanding the key focus areas and top selling therapeutics of leading companies.
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Table of Contents
TOC
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10
2 Substance Abuse Therapeutics Market to 2018 - Introduction 12
Figure 52: Substance Abuse Therapeutics Market, Global, Major R&D Licensing Deals By Geography, 2007-2012 88
Figure 53: GBI Research Market Forecasting Model 96
Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities published by GBI Research in August 22, 2012. This report consists of Pages: 97 and the price starts from US $ 3500.
Press Release
Substance Abuse Therapeutic Market Expected to Grow at a CAGR of 5.3% to Reach $12.7 Billion in 2018
August 31st, 2012
Global Information Inc. would like to present a new market research report, "Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities" by GBI Research.
The Substance Abuse Therapeutics Market will Show Only Moderate Growth, Despite High Potential
The overall substance abuse therapeutic market was valued at $8.8 billion in 2011 and is expected to reach $12.7 billion in 2018, at a Compound Annual Growth Rate (CAGR) of 5.3% between 2011 and 2018.
Despite government awareness campaigns, improved treatment access and public health efforts, the substance abuse therapeutic market is not growing at the high rate that might be expected considering the patient populations available. This is because of the difficulties in persuading patients to seek and accept treatment and the problems of compliance and relapse.
Recent years have seen a few discontinuations of products in the substance abuse therapeutics market. One of the major instances of this was Sanofi terminating the development of its smoking cessation product Dianicline due to inadequate differentiation from Chantix (varenicline).
In July 2009, the US Food and Drug Administration (FDA) added a black box label warning on neuropsychiatric effects to the Chantix and Zyban (buprenorphine) labels, which is likely to impede their growth during the forecast period. Further concerns have since been raised over the drugs regarding increasing behavioral changes and suicidal thoughts, and Chantix has more recently raised concerns over claims of increased risk of heart attacks in healthy patients.
Shortage of Major Alternate Therapies to Vivitrol is a Major Concern for the Alcohol Dependence Market
The alcohol dependence market was valued at $284m in 2011 and is expected to reach $645m in 2018, growing at a CAGR of 12.4% between 2011 and 2018. Growth shall be driven primarily by a few major products that are expected to be launched during the forecast period, such as Selincro (nalfemene).
Bioties Nalmefene, an opioid antagonist, is expected to launch in early 2013. Nalmefene is a novel treatment option, and its anticipated lack of an alcohol abstinence requirement prior to treatment and as-needed dosing regimen will make the drug an attractive treatment option for patients. However, based on clinical data to date, the drug is not expected to overtake Vivitrols (naltrexone) prescription sales. It faces resistance as it represents a new treatment paradigm, encouraging reduction rather than abstinence.
The market shall also be driven significantly by increasing patient awareness, leading to a higher treatment-seeking rate and better compliance and persistence towards the various therapies.
The Smoking Cessation Market has Huge Unmet Needs as Promising Late-Stage Vaccine Fails
The pipeline is sparse for the treatment of smoking cessation; the focus of innovation for future products is on patient progression and compliance, and the key players in the market acknowledge the need for this. It is too easy for a patient to stop their treatment in order to regain the positive effects of nicotine which they crave. The main opportunity for growth is therefore in the increase of patient compliance; novel methods of drug delivery such as extended release vaccines are vital for the improvement of efficacy. The leading product in the smoking cessation pipeline is an immunotherapeutic vaccine designed to address these needs.
The late-stage failure of clinical trials for NicVAX (Nicotine Conjugate Vaccine) has come as a blow to Nabi Pharmaceuticals, whose extended release anti-smoking vaccine, was the most promising in the pipeline, and would have driven market growth considerably. There is now considerable doubt over whether NicVAX will reach the market, prolonging the unmet need in this indication for more efficacious extended release treatments.
Increasing concerns over the safety of Pfizers marketed product Chantix, which has the largest market share of any prescription treatment on the market, creates further unmet need in terms of safety. The development of a comparable product with an increased safety profile could damage Chantixs revenues considerably, and drive the market as a whole through increased prescription rate.
The Drug Abuse Market has Huge Unmet Needs Due to a Lack of Approved Treatment Options for Cocaine Abuse
Although cocaine abuse is almost five times more prevalent than opioid abuse in the US, opioid abuse therapeutics make up 60% of overall revenues of the substance abuse therapeutic market due to the very high Annual Cost of Treatment (ACT). Pharmacological therapies for cocaine abuse are invariably off-label treatments, which are often out of patent and therefore have a low ACT. There is the opportunity for developing a specific treatment for the indication of cocaine dependence with greater efficacy than the current off-label treatment options. The emergence of such treatments would increase the ACT and drive market revenues.
